维持和重新编程前列腺癌中的基因组雄激素受体活性。
Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.
机构信息
Prostate Cancer Research Group, Centre for Molecular Medicine Norway (NCMM), University of Oslo and Oslo University Hospitals, N-0318 Oslo, Norway;Departments of Cancer Prevention and Urology, Institute of Cancer Research and Oslo University Hospitals, N-0424 Oslo, Norway;Uro-Oncology Research Group, Cambridge Research Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
出版信息
Nat Rev Cancer. 2014 Mar;14(3):187-98. doi: 10.1038/nrc3678.
Prostate cancer treatment is dominated by strategies to control androgen receptor (AR) activity. AR has an impact on prostate cancer development through the regulation of not only transcription networks but also genomic stability and DNA repair, as manifest in the emergence of gene fusions. Whole-genome maps of AR binding sites and transcript profiling have shown changes in the recruitment and regulatory effect of AR on transcription as prostate cancer progresses. Defining other factors that are involved in this reprogramming of AR function gives various opportunities for cancer detection and therapeutic intervention.
前列腺癌的治疗主要以控制雄激素受体 (AR) 活性的策略为主。AR 通过调节不仅转录网络，而且基因组稳定性和 DNA 修复，对前列腺癌的发展产生影响，表现在基因融合的出现。AR 结合位点的全基因组图谱和转录谱分析显示，随着前列腺癌的进展，AR 对转录的募集和调节作用发生变化。确定参与 AR 功能这种重编程的其他因素为癌症检测和治疗干预提供了各种机会。
Zotero 插件